Go Pro
NASDAQ:IXHL

Incannex Healthcare (IXHL) Stock Price, News & Analysis

Incannex Healthcare logo
$3.03 +0.09 (+3.13%)
As of 10:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Incannex Healthcare Stock (NASDAQ:IXHL)

Advanced

Key Stats

Today's Range
$2.92
$3.06
50-Day Range
$2.91
$3.99
52-Week Range
$2.49
$27.69
Volume
23,827 shs
Average Volume
370,800 shs
Market Capitalization
$36.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Hold

Company Overview

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation. Lead programs target pulmonary hypertension, refractory epilepsy, and chronic cough, with formulations designed for inhalation delivery. In addition, Incannex is advancing studies in post-viral syndromes such as long COVID, exploring the anti-inflammatory and neuroprotective properties of its compounds. Preclinical work and early-phase trials have provided proof-of-concept data supporting further clinical investigation.

Incannex holds an expanding portfolio of patents covering its inhalation devices, formulation technologies and combination drug compositions. The company collaborates with contract research organizations and academic institutions to oversee regulatory filings, toxicology studies and pharmacokinetic assessments. By building a comprehensive intellectual property estate, Incannex aims to position itself for strategic partnerships or licensing agreements upon completion of pivotal trials.

Founded in 2017, Incannex has grown from a research start-up into a development-stage biotech enterprise. Its management team brings experience in drug development, regulatory affairs and commercial strategy, guiding the company through cross-listings on the Australian Securities Exchange and the NASDAQ. With clinical programs underway in Australia and the U.S., Incannex Healthcare is advancing toward proof-of-efficacy studies that could inform its pathway to market for novel cannabinoid-based therapeutics.

AI Generated. May Contain Errors.

Incannex Healthcare Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

IXHL MarketRank™: 

Incannex Healthcare scored higher than 33% of companies evaluated by MarketBeat, and ranked 731st out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Incannex Healthcare has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Incannex Healthcare has a consensus price target of $18.00, representing about 512.2% upside from its current price of $2.94.

  • Amount of Analyst Coverage

    Incannex Healthcare has only been the subject of 2 research reports in the past 90 days.

  • Read more about Incannex Healthcare's stock forecast and price target.
  • Earnings Growth

    Earnings for Incannex Healthcare are expected to grow in the coming year, from ($1.38) to ($1.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Incannex Healthcare is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Incannex Healthcare is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Incannex Healthcare has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Incannex Healthcare's valuation and earnings.
  • Percentage of Shares Shorted

    8.51% of the float of Incannex Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Incannex Healthcare has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incannex Healthcare has recently increased by 97.37%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Incannex Healthcare does not currently pay a dividend.

  • Dividend Growth

    Incannex Healthcare does not have a long track record of dividend growth.

  • Search Interest

    9 people have searched for IXHL on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.33% of the stock of Incannex Healthcare is held by insiders.

  • Percentage Held by Institutions

    0.43% of the stock of Incannex Healthcare is held by institutions.

  • Read more about Incannex Healthcare's insider trading history.
Receive IXHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incannex Healthcare and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IXHL Stock News Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Headlines

IXHL Stock Analysis - Frequently Asked Questions

Incannex Healthcare's stock was trading at $10.74 at the start of the year. Since then, IXHL shares have decreased by 72.6% and is now trading at $2.94.

Incannex Healthcare Inc. (NASDAQ:IXHL) announced its quarterly earnings data on Friday, February, 13th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).

Incannex Healthcare's stock reverse split on Friday, February 27th 2026.The 1-30 reverse split was announced on Wednesday, February 25th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Jabil (JBL).

Company Calendar

Last Earnings
2/13/2026
Today
8/03/2026
Next Earnings (Estimated)
9/02/2026
Fiscal Year End
6/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IXHL
CIK
1873875
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$18.00
Potential Upside/Downside
+493.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46.88 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-81.01%
Return on Assets
-76.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
41.56
Quick Ratio
41.56

Sales & Book Value

Annual Sales
$90 thousand
Price / Sales
403.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.07 per share
Price / Book
1.46

Miscellaneous

Outstanding Shares
11,970,000
Free Float
11,806,000
Market Cap
$36.29 million
Optionable
Not Optionable
Beta
6.98
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:IXHL) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners